Part D Gap Rebates Boost Medicare Rx Spending To 9% Gain In 2010
This article was originally published in The Pink Sheet Daily
Drug spending by the Medicare program increased more than by Medicaid or by private payers in 2010, according to an analysis by CMS; expenditures in Medicaid and by private insurance were level with the previous year and consumer out-of-pocket spending declined. Total drug spending across-the-board rose 1.2% to $259 billion.
You may also be interested in...
Updates on Medicare’s ACO program, drug spending trends and Medicare coverage of IVIG.
The pharmaceutical industry proposal to provide 50 percent discounts on the price of branded drugs for Medicare Part D beneficiaries in the donut hole would wind up costing the federal government $17.4 billion over 10 years, according to estimates by the Congressional Budget Office and the Joint Committee on Taxation released Sept. 16
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.